Relationship Between Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Disease Outcome in Adult-Onset Asthma

References

• Global Strategy for Asthma Management and Prevention; 2019. Available from: www.ginasthma.org/. Accessed April 21, 2022.
   Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716–725. doi:10.1038/nm.2678
   PubMed Web of Science ®Google Scholar
• de Nijs SB, Venekamp LN, Bel EH. Adult-onset asthma: is it really different? Eur Respir Rev. 2013;22:44–52. doi:10.1183/09059180.00007112
   PubMedGoogle Scholar
• Ilmarinen P, Tuomisto LE, Kankaanranta H. Phenotypes, risk factors, and mechanisms of adult-onset asthma. Mediators Inflamm. 2015;2015:514868. doi:10.1155/2015/514868
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Bønnelykke K. Long-term studies of the natural history of asthma in childhood. J Allergy Clin Immunol. 2010;126:187–189. doi:10.1016/j.jaci.2010.07.011
   PubMed Web of Science ®Google Scholar
• Kankaanranta H, Tuomisto LE, Ilmarinen P. Age-specific incidence of new asthma diagnoses in Finland. J Allergy Clin Immunol Pract. 2017;5(189–191.e3):189–191.e3. doi:10.1016/j.jaip.2016.08.015
   PubMed Web of Science ®Google Scholar
• Sood A, Qualls C, Schuyler M, et al. Adult-onset asthma becomes the dominant phenotype among women by age 40 years. The Longitudinal CARDIA Study. Ann Am Thorac Soc. 2013;10:188–197. doi:10.1513/AnnalsATS.201212-115OC
   PubMedGoogle Scholar
• Ploug M, Behrendt N, Løber D, Danø K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb Hemost. 1991;17:183–193. doi:10.1055/s-2007-1002608
   PubMed Web of Science ®Google Scholar
• Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27:157–172. doi:10.1155/2009/504294
   PubMed Web of Science ®Google Scholar
• Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the urokinase-type Plasminogen Activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front Oncol. 2018;8:24. doi:10.3389/fonc.2018.00024
   PubMed Web of Science ®Google Scholar
• Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997;16:7279–7286. doi:10.1093/emboj/16.24.7279
   PubMed Web of Science ®Google Scholar
• Haupt TH, Rasmussen LJH, Kallemose T, et al. Healthy lifestyles reduce suPAR and mortality in a Danish general population study. Immun Ageing I A. 2019;16:1–8. doi:10.1186/s12979-018-0141-8
   PubMed Web of Science ®Google Scholar
• Haupt TH, Petersen J, Ellekilde G, et al. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. Crit Care. 2012;16:R130. doi:10.1186/cc11434
   PubMed Web of Science ®Google Scholar
• Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268:296–308. doi:10.1111/j.1365-2796.2010.02252.x
   PubMed Web of Science ®Google Scholar
• Garnæs E, Mortensen C, Hobolth L, Andersen O, Nehlin J, Møller S. Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis. PLoS One. 2019;14:e0220697. doi:10.1371/journal.pone.0220697
   PubMed Web of Science ®Google Scholar
• Eugen-Olsen J, Giamarellos-Bourboulis EJ. suPAR: the unspecific marker for disease presence, severity and prognosis. Int J Antimicrob Agents. 2015;46(Suppl 1):33. doi:10.1016/j.ijantimicag.2015.10.011
   PubMed Web of Science ®Google Scholar
• Stewart CE, Nijmeh HS, Brightling CE, Sayers I. uPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium. Thorax. 2012;67:477–487. doi:10.1136/thoraxjnl-2011-200508
   PubMed Web of Science ®Google Scholar
• Portelli MA, Moseley C, Stewart CE, et al. Airway and peripheral urokinase plasminogen activator receptor is elevated in asthma, and identifies a severe, nonatopic subset of patients. Allergy. 2017;72:473–482. doi:10.1111/all.13046
   PubMed Web of Science ®Google Scholar
• Portelli MA, Siedlinski M, Stewart CE, et al. Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. FASEB J. 2014;28:923–934. doi:10.1096/fj.13-240879
   PubMed Web of Science ®Google Scholar
• Xiao W, Hsu YP, Ishizaka A, Kirikae T, Moss RB. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest. 2005;128:2316–2326. doi:10.1378/chest.128.4.2316
   PubMed Web of Science ®Google Scholar
• Håkansson KEJ, Rasmussen LJH, Godtfredsen NS, et al. The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma - a retrospective cohort study. Respir Res. 2019;20:254–258. doi:10.1186/s12931-019-1234-4
   PubMed Web of Science ®Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Kankaanranta H, Ilmarinen P, Kankaanranta T, Tuomisto LE. Seinäjoki Adult Asthma Study (SAAS): a protocol for a 12-year real-life follow-up study of new-onset asthma diagnosed at adult age and treated in primary and specialised care. npj Prim Care Respir Med. 2015;25:15042. doi:10.1038/npjpcrm.2015.42
   PubMed Web of Science ®Google Scholar
• Haahtela T, Tuomisto LE, Pietinalho A, et al. A 10 year asthma programme in Finland: major change for the better. Thorax. 2006;61:663–670. doi:10.1136/thx.2005.055699
   PubMed Web of Science ®Google Scholar
• Barley EA, Quirk FH, Jones PW. Asthma health status measurement in clinical practice: validity of a new short and simple instrument. Respir Med. 1998;92:1207–1214. doi:10.1016/S0954-6111(98)90423-1
   PubMed Web of Science ®Google Scholar
• Schatz M, Sorkness CA, Li JT, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117:549–556. doi:10.1016/j.jaci.2006.01.011
   PubMed Web of Science ®Google Scholar
• Global Strategy for Asthma Management and Prevention; 2010. Available from: www.ginasthma.org/. Accessed April 21, 2022.
   Google Scholar
• Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37–43. doi:10.1016/S0140-6736(12)60240-2
   PubMed Web of Science ®Google Scholar
• Ilmarinen P, Tuomisto LE, Niemelä O, et al. Comorbidities and elevated IL-6 associate with negative outcome in adult-onset asthma. Eur Respir J. 2016;48:1052–1062. doi:10.1183/13993003.02198-2015
   PubMed Web of Science ®Google Scholar
• Vähätalo I, Ilmarinen P, Tuomisto LE, Niemelä O, Kankaanranta H. Inhaled corticosteroids and asthma control in adult-onset asthma: 12-year follow-up study. Respir Med. 2018;137:70–76. doi:10.1016/j.rmed.2018.02.025
   PubMed Web of Science ®Google Scholar
• Global Strategy for Asthma Management and Prevention; 2002. Available from: www.ginasthma.org/. Accessed April 21, 2022.
   Google Scholar
• Ivancsó I, Toldi G, Bohács A, et al. Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy. PLoS One. 2013;8:e60697. doi:10.1371/journal.pone.0060697
   PubMed Web of Science ®Google Scholar
• Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75:311–325. doi:10.1111/all.13985
   PubMed Web of Science ®Google Scholar
• Rasmussen LJH, Petersen JEV, Eugen-Olsen J. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a biomarker of systemic chronic inflammation. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.780641
   Web of Science ®Google Scholar
• Cundall M, Sun Y, Miranda C, Trudeau JB, Barnes S, Wenzel SE. Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J Allergy Clin Immunol. 2003;112:1064–1071. doi:10.1016/j.jaci.2003.08.013
   PubMed Web of Science ®Google Scholar
• Hosoki K, Ying S, Corrigan C, et al. Analysis of a panel of 48 cytokines in BAL fluids specifically identifies IL-8 levels as the only cytokine that distinguishes controlled asthma from uncontrolled asthma, and correlates inversely with FEV1. PLoS One. 2015;10:e0126035. doi:10.1371/journal.pone.0126035
   PubMed Web of Science ®Google Scholar
• Gussen H, Hohlstein P, Bartneck M, et al. Neutrophils are a main source of circulating suPAR predicting outcome in critical illness. J Intensive Care. 2019;7:1. doi:10.1186/s40560-019-0381-5
   Web of Science ®Google Scholar
• Wood LG, Baines KJ, Fu J, Scott HA, Gibson PG. The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma. Chest. 2012;142:86–93. doi:10.1378/chest.11-1838
   PubMed Web of Science ®Google Scholar
• Fu JJ, Baines KJ, Wood LG, Gibson PG. Systemic inflammation is associated with differential gene expression and airway neutrophilia in asthma. OMICS. 2013;17:187–199. doi:10.1089/omi.2012.0104
   PubMed Web of Science ®Google Scholar
• Gangestad SW, Gangestad SW. Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. 2018;70:61–75. doi:10.1016/j.bbi.2018.02.013
   PubMed Web of Science ®Google Scholar
• Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012;8:1281–1290. doi:10.7150/ijbs.4874
   PubMed Web of Science ®Google Scholar
• Tuomisto LE, Ilmarinen P, Niemelä O, Haanpää J, Kankaanranta T, Kankaanranta H. A 12-year prognosis of adult-onset asthma: seinäjoki adult asthma study. Respir Med. 2016;117:223–229. doi:10.1016/j.rmed.2016.06.017
   PubMed Web of Science ®Google Scholar
• Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 2002;71:1523–1534. doi:10.1016/S0024-3205(02)01921-5
   PubMed Web of Science ®Google Scholar
• Rasmussen LJ, Ladelund S, Haupt TH, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A Retrospective Cohort Study Emerg Med J. 2016;33:769–775.
   Google Scholar
• Hodges GW, Bang CN, Wachtell K, Eugen-Olsen J, Jeppesen JL. suPAR: a new biomarker for cardiovascular disease? Can J Cardiol. 2015;31:1293–1302. doi:10.1016/j.cjca.2015.03.023
   PubMed Web of Science ®Google Scholar
• Langkilde A, Petersen J, Klausen HH, Henriksen JH, Eugen-Olsen J, Andersen O. Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort study. PLoS One. 2012;7:e51698. doi:10.1371/journal.pone.0051698
   PubMed Web of Science ®Google Scholar
• Haastrup E, Grau K, Eugen-Olsen J, Thorball C, Kessing LV, Ullum H. Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants. PLoS One. 2014;9:e110555. doi:10.1371/journal.pone.0110555
   PubMed Web of Science ®Google Scholar
• Ilmarinen P, Tuomisto LE, Niemelä O, Kankaanranta H. Prevalence of patients eligible for anti-IL-5 treatment in a cohort of adult-onset asthma. J Allergy Clin Immunol Pract. 2019;7(165–174.e4):165–174.e4. doi:10.1016/j.jaip.2018.05.032
   PubMed Web of Science ®Google Scholar